Skip to search formSkip to main contentSkip to account menu

natalizumab Injection [Tysabri]

National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

15 ML natalizumab 20 MG/ML Injection [Tysabri]
InjectionTysabri

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
4-Week toxicity study of biosimilar natalizumab in comparison to Tysabri® by repeated intravenous infusion to cynomolgus monkeys
Abstract The objective of the study was to obtain information on the toxicity of biosimilar natalizumab (PB006) in comparison to… 
Review
2015
Review
2015
Spanish consensus on the use of natalizumab (Tysabri®)-2013
2014
2014
Interference of therapeutic monoclonal immunoglobulins in the investigation of M-proteins
2014
2014
Psychose bei hochaktivem MS-Verlauf
ZusammenfassungDas therapeutische Angebot im Bereich der multiplen Sklerose (MS) hat sich in den letzten Jahren erheblich… 
2011
2011
Risikostratifizierung einer progressiven multifokalen Leukenzephalopathie unter Natalizumab
ZusammenfassungDie JC-Virus (JCV)-assoziierte progressive multifokale Leukenzephalopathie (PML) ist eine schwerwiegende unerw… 
2011
2011
[Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?].
Natalizumab (Tysabri®) is the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS… 
2009
2009
Iatrogenic immunosuppression with biologics in MS
Natalizumab (Tysabri®, Biogen Idec Inc., Cambridge, MA) is a recombinant humanized monoclonal antibody that binds to the α4 chain… 
2008
2008
The Use of Disease-Modifying Agents in Multiple Sclerosis - by the Canadian Network of MS Clinics
  • P. O'Connor
  • Canadian Journal of Neurological Sciences…
  • 2008
  • Corpus ID: 23698338
Health Canada approved medications for the treatment of multiple sclerosis (MS): Avonex® (Interferon Beta 1a), Betaseron… 
Review
2007
Review
2007
Advances in Treating Multiple Sclerosis
The approval of three interferons-beta (IFNβ) and of glatiramer acetate (GA) by the US Food and Drug Administration (FDA) in the… 
1978
1978
Talking to Your Doctor
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)